c-Jun N-terminal kinase inhibitors: a patent review (2010 – 2014)

Bibliography

• Grant SK. Therapeutic Protein Kinase Inhibitors. Cell Mol Life Sci 2009;66(7):1163-77
   PubMed Web of Science ®Google Scholar
• Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (Washington, DC, U S) 2002;298(5600):1911-12
   PubMed Web of Science ®Google Scholar
• Cui J, Zhang M, Zhang Y-Q, et al. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin 2007;28(5):601-8
   PubMed Web of Science ®Google Scholar
• Gupta S, Barret T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15(11):2760-70
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9(8):537-49
   PubMed Web of Science ®Google Scholar
• Whitmarsh AJ, Cavanagh J, Tournier C, et al. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science (Washington, D C) 1998;281(5383):1671-4
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006;70(4):1061-95
   PubMed Web of Science ®Google Scholar
• Koch P, Gehringer M, Laufer SA. Inhibitors of c-jun N-terminal kinases: an update. J Med Chem 2015;58(1):72-95
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. the protein kinase complement of the human genome. Science (Washington, DC, U S) 2002;298(5600):1912-16; 33-34
   PubMed Web of Science ®Google Scholar
• Graczyk PP. JNK inhibitors as anti-inflammatory and neuroprotective agents. Future Med Chem 2013;5(5):539-51
   PubMed Web of Science ®Google Scholar
• Perrin V, Dufour N, Raoul C, et al. Implication of the JNK pathway in a rat model of Huntington’s disease. Exp Neurol 2009;215(1):191-200
   PubMed Web of Science ®Google Scholar
• Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor α (TNF-α) translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol Cell Biol 1997;17(11):6274-82
   PubMed Web of Science ®Google Scholar
• Guma M, Ronacher LM, Firestein GS, et al. JNK-1 deficiency limits macrophage-mediated antigen-induced arthritis. Arthritis Rheum 2011;63(6):1603-12
   PubMedGoogle Scholar
• Vallerie SN, Hotamisligil GS. The role of JNK proteins in metabolism. Sci Transl Med 2010;2(60):60rv5
   PubMed Web of Science ®Google Scholar
• Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171(1):24-37
   PubMed Web of Science ®Google Scholar
• Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98(24):13681-6
   PubMed Web of Science ®Google Scholar
• Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-36
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Reddy PA. Small molecule JNK (c-Jun N-terminal kinase) inhibitors. J Med Chem 2010;53(8):3005-12
   PubMed Web of Science ®Google Scholar
• Stebbins JL, De SK, Pavlickova P, et al. Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. J Med Chem 2011;54(18):6206-14
   PubMed Web of Science ®Google Scholar
• Zhang T, Inesta-Vaquera F, Niepel M, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol (Oxford, U K) 2012;19(1):140-54
   PubMed Web of Science ®Google Scholar
• Krenitsky VP, Delgado M, Nadolny L, et al. Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury. Bioorg Med Chem Lett 2012;22(3):1427-32
   PubMed Web of Science ®Google Scholar
• Haynes N-E, Scott NR, Chen LC, et al. Identification of an adamantyl azaquinolone JNK selective inhibitor. ACS Med Chem Lett 2012;3(9):764-8
   PubMed Web of Science ®Google Scholar
• Zheng K, Iqbal S, Hernandez P, et al. Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem 2014;57(23):10013-30
   PubMed Web of Science ®Google Scholar
• Gaillard P, Jeanclaude-Etter I, Ardissone V, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 2005;48(14):4596-607
   PubMed Web of Science ®Google Scholar
• PGL5001 Proof of Concept Study in Inflammatory Endometriosis - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01630252?term=NCT01630252&rank=1 [Accessed 14 January 2015]
   Google Scholar
• Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT00802425 [Accessed 12 January 2015]
   Google Scholar
• Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02235272 [Accessed 12 January 2015]
   Google Scholar
• Bogoyevitch MA, Ngoei KRW, Zhao TT, et al. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 2010;1804(3):463-75
   PubMed Web of Science ®Google Scholar
• Arzeno HB, Filonova L, Goldstein DM, et al. Preparation of 2-aminopyrimidine derivatives as JNK inhibitors. WO2011151358A1; 2011
   Google Scholar
• Buettelmann B, Goyal B, Palmer WS. Preparation of cyclohexylaminopyrimidinylimidazopyridine derivatives for use as JNK modulators. WO2010097335A1; 2010
   Google Scholar
• Gong L, Han X, Makra F, et al. Pyrimidine derivatives as JNK inhibitors and their preparation and use for the treatment of JNK-mediated diseases. US20110034470A1; 2011
   Google Scholar
• Gong L, Jahangir A, Reuter DC. Pyrimidin-2-ylamine derivatives as JNK inhibitors and their preparation and use for the treatment of inflammation. WO2010069833A1; 2010
   Google Scholar
• Gong L, Tan Y-C. Preparation of 2-aminopyrimidine derivatives as JNK inhibitors. WO2011151357A1; 2011
   Google Scholar
• Palmer WS, Alam M, Arzeno HB, et al. Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): Kinase profiling guided optimization of a 1,2,3-benzotriazole lead. Bioorg Med Chem Lett 2013;23(5):1486-92
   PubMed Web of Science ®Google Scholar
• Goldstein DM, Gong L, Michoud C, et al. Preparation of aminopyrimidinylbenzotriazoles as kinase modulators. WO2008028860A1; 2008
   Google Scholar
• Gong L, Han X, Silva T, et al. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): Optimization for JNK potency and physicochemical properties. Bioorg Med Chem Lett 2013;23(12):3565-9
   PubMed Web of Science ®Google Scholar
• Boice GN, Gong L, McCaleb KL, et al. Pyrimidinyl pyridone derivatives as inhibitors of JNK, their preparation and use for treatment of diseases associated with excessive JNK activity. WO2010046273A2; 2010
   Google Scholar
• Cheung AW-H, Guertin KR, Haynes N-E, et al. Preparation of adamantane derivatives for treatment of JNKs-mediated disorders. WO2012136684A1; 2012
   Google Scholar
• Gong L, Tan Y-C, Boice G, et al. Discovery of a novel series of 4-quinolone JNK inhibitors. Bioorg Med Chem Lett 2012;22(24):7381-7
   PubMed Web of Science ®Google Scholar
• Bilotta JA, Cheung AW-H, Firooznia F, et al. Aminomethylquinolone compounds as JNK inhibitors and their preparation. WO2013007676A1; 2013
   Google Scholar
• Beauchamps MG, Harris LM, Kothare MA, et al. Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol for treatment of cancer, inflammation and autoimmune diseases. WO2011071491A1; 2011
   Google Scholar
• A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01466725 [Accessed 10 January 2015]
   Google Scholar
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT01203943 [Accessed 10 January 2015]
   Google Scholar
• Albers R, Ayala L, Clareen S, et al. Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith. Google Patents; 2007
   Google Scholar
• Albers R, Ayala L, Clareen SS, et al. Preparation of haloaryl substituted aminopurines for use as a prodrug in the treatment of cancers, cardiovascular or renal diseases. WO2006076595A1; 2006
   Google Scholar
• Plantevin Krenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012;22(3):1433-8
   PubMed Web of Science ®Google Scholar
• Bennett BL, Elsner J, Erdman P, et al. Preparation of substituted diaminocarboxamide and diaminocarbonitrile pyrimidines as JNK pathway inhibitors. WO2012145569A1; 2012
   Google Scholar
• Graczyk P, Khan A, Bhatia G, et al. Preparation of pyrrolo[2,3-b]pyrimidines as inhibitors of c-Jun N-terminal kinases (JNKs) inhibitors for the treatment of neurodegenerative disorders. WO2004078756A2; 2004
   Google Scholar
• Graczyk PP, Dimopoulos P, Khan A, et al. 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase and their preparation. WO2008095944A1; 2008
   Google Scholar
• Graczyk P, Bhatia GS. Diazaindole derivatives, their preparation and therapeutic use as inhibitors of c-Jun N-terminal kinase. WO2010015803A1; 2010
   Google Scholar
• Gehringer M, Forster M, Pfaffenrot E, et al. Novel hinge-binding motifs for janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. ChemMedChem 2014;9(11):2516-27
   PubMed Web of Science ®Google Scholar
• Gray N, Zhang T. Preparation of pyrimidineamine compounds as inhibitors of c-Jun-N-terminal kinase (JNK). WO2013074986A1; 2013
   Google Scholar
• Knapp S, Arruda P, Blagg J, et al. A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 2013;9(1):3-6
   PubMed Web of Science ®Google Scholar
• Kamenecka T, Jiang R, Song X, et al. Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal Kinase (JNK) inhibitors. J Med Chem 2010;53(1):419-31
   PubMed Web of Science ®Google Scholar
• Javaherian A. Screening methods for identifying agents that modulate DNA-binding proteins TDP-43 and therapeutic uses thereof in the treatment of TDP-43 proteinopathies. WO2013169793A2; 2013
   Google Scholar
• Huang L, Liu S, Lunney EA, et al. Substituted 2-amino-fused heterocyclic compounds as JNK modulators and their preparation, pharmaceutical compositions and use in the treatment of diabetes and related diseases. WO2007125405A2; 2007
   Google Scholar
• Pellecchia M. Bi-dentate compounds as kinase inhibitors. WO2012083092A2; 2012
   Google Scholar
• Heo Y-S, Kim S-K, Seo CI, et al. Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J 2004;23(11):2185-95
   PubMed Web of Science ®Google Scholar
• Yang X, Hadida Ruah SS, Grootenhuis PDJ, et al. Preparation of phenyloxodihydroquinolinecarboxamide derivatives for use as cystic fibrosis transmembrane conductance regulator modulators. WO2010108155A1; 2010
   Google Scholar
• De SK, Barile E, Chen V, et al. Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase. Bioorg Med Chem 2011;19(8):2582-8
   PubMed Web of Science ®Google Scholar
• Bonny C. Cell-permeable peptide inhibitors of the JNK signal transduction pathway and their therapeutic use. WO2001027268A2; 2001
   Google Scholar
• Bonny C. Cell-permeable peptide inhibitors of JNK (c-Jun amino terminal kinase) signal transduction pathway and their therapeutic use. WO2007031280A2; 2007
   Google Scholar
• Bonny C. Novel (poly-)peptide JNK inhibitor molecules. WO2011160653A1; 2011
   Google Scholar
• Bonny C, Oberson A, Negri S, et al. Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes 2001;50(1):77-82
   PubMed Web of Science ®Google Scholar
• Combette J-M, Deloche C, Abadie C. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of inflammatory eye disease. WO2012048721A1; 2012
   Google Scholar
• Combette J-M, Deloche C. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of dry eye syndrome. WO2013079213A1; 2013
   Google Scholar
• Kaoud TS, Mitra S, Lee S, et al. Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem Biol 2011;6(6):658-66
   PubMed Web of Science ®Google Scholar
• Combette J-M, Deloche C. Novel JNK inhibitory (poly-)peptides for treatment of various diseases. WO2013091670A1; 2013
   Google Scholar
• Efficacy and Safety of XG-104 for the Treatment of Dry Eye - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02235259?term=xg-104&rank=1 [Accessed 13 January 2015]
   Google Scholar
• Sham HL, Konradi AW, Hom RK, et al. Preparation of N-(thiophen-3-yl)acetamide derivatives as inhibitors of JNK N-terminal kinase. WO2010091310A1; 2010
   Google Scholar
• Hom RK, Bowers S, Sealy JM, et al. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Bioorg Med Chem Lett 2010;20(24):7303-7
   PubMed Web of Science ®Google Scholar
• Bowers S, Truong AP, Neitz RJ, et al. Design and synthesis of a novel, orally active, brain penetrant, TRI-substituted thiophene based JNK inhibitor. Bioorg Med Chem Lett 2011;21(6):1838-43
   PubMed Web of Science ®Google Scholar
• Bowers S, Truong AP, Jeffrey Neitz R, et al. Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration. Bioorg Med Chem Lett 2011;21(18):5521-7
   PubMed Web of Science ®Google Scholar
• Zimmermann MO, Lange A, Wilcken R, et al. Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. Future Med Chem 2014;6(6):617-39
   PubMed Web of Science ®Google Scholar
• Cellamare S, Carotti A, Stefanachi A, et al. Galloyl benzamide-based compounds as JNK modulators. WO2014170706A1; 2014
   Google Scholar
• Pellicani RZ, Stefanachi A, Niso M, et al. Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein. J Med Chem 2012;55(1):424-36
   PubMed Web of Science ®Google Scholar
• Singh J, Petter RC, Baillie TA, et al. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10(4):307-17
   PubMed Web of Science ®Google Scholar
• Serafimova IM, Pufall MA, Krishnan S, et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat Chem Biol 2012;8(5):471-6
   PubMed Web of Science ®Google Scholar
• Backes AC, Zech B, Felber B, et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov 2008;3(12):1427-49
   PubMed Web of Science ®Google Scholar
• Kuglstatter A, Ghate M, Tsing S, et al. X-ray crystal structure of JNK2 complexed with the p38α inhibitor BIRB 796: Insights into the rational design of DFG-out binding MAP kinase inhibitors. Bioorg Med Chem Lett 2010;20(17):5217-20
   PubMed Web of Science ®Google Scholar
• Taylor SS, Kornev AP. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 2011;36(2):65-77
   PubMed Web of Science ®Google Scholar
• Taylor DM, Moser R, Regulier E, et al. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington’s disease via additive effects of JNK and p38 inhibition. J Neurosci 2013;33(6):2313-25
   PubMed Web of Science ®Google Scholar
• Muth F, Günther M, Bauer SM, et al. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. J Med Chem 2015;58(1):443-56
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Bradke F. The DLK signalling pathway-a double-edged sword in neural development and regeneration. EMBO Rep 2013;14(7):605-14
   PubMed Web of Science ®Google Scholar